TY - JOUR T1 - Short-term outcomes of COVID-19 and risk factors for progression JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00990-2020 VL - 55 IS - 5 SP - 2000990 AU - Li Long AU - Xiansheng Zeng AU - Xu Zhang AU - Wei Xiao AU - E Guo AU - Wenzhi Zhan AU - Xuejiao Yang AU - Chunyan Li AU - Caiyun Wu AU - Tingting Xu AU - Chen Zhan AU - Yuehan Chen AU - Mei Jiang AU - Nanshan Zhong AU - Kefang Lai Y1 - 2020/05/01 UR - http://erj.ersjournals.com/content/55/5/2000990.abstract N2 - Coronavirus disease 2019 (COVID-19) has now become a worldwide health concern. The severity of COVID-19 has been classified as mild, moderate, severe and critical [1]. To date, there have been a few studies focused on the clinical course and outcome of critical cases [2–4]. However, information regarding outcomes of mild-to-moderate cases is lacking, despite the fact that mild-to-moderate cases have accounted for approximately 80% of laboratory-confirmed patients [1, 5]. This study aimed to investigate short-term outcomes of patients rated with different severities on admission, and to identify risk factors for progression, thereby helping the management of COVID-19 in clinical practice.With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0Our thanks go to all doctors and nurses in The First People's Hospital of Jingzhou, and Xiangyang Central Hospital. ER -